Literature DB >> 11807764

Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors.

Ali Ozuer1, James B Wechuck, William F Goins, Darren Wolfe, Joseph C Glorioso, Mohammad M Ataai.   

Abstract

Herpes simplex virus type-1 (HSV-1) represents a unique vehicle for the introduction of foreign DNA to cells of a variety of tissues. The nature of the vector, the cell line used for propagation of the vector, and the culture conditions will significantly impact vector yield. An ideal vector should be deficient in genes essential for replication as well as those that contribute to its cytotoxicity. Advances in the engineering of replication-defective HSV-1 vectors to reduce vector-associated cytotoxicity and attain sustained expression of target genes make HSV-1 an attractive gene-delivery vehicle. However, the yield of the less-cytotoxic vectors produced in standard tissue-culture systems is at least three order of magnitudes lower than that achieved with wild-type virus. The low overall yield and the complexity involved in the preparation of HSV vectors at high concentrations represent major obstacles in use of replication-defective HSV-derived vectors in gene therapy applications. In this work, the dependence of the vector yield on the genetic background of the virus is examined. In addition, we investigated the production of the least toxic, lowest-yield vector in a CellCube bioreactor system. After initial optimization of the operational parameters of the cellcube system, we were able to attain virus yields similar to or better than those values attained using the tissue culture flask system for vector production with significant savings with respect to time, labor, and cost. Copyright 2002 John Wiley & Sons, Inc. Biotechnol Bioeng 77: 685-692, 2002; DOI 10.1002/bit.10162

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807764     DOI: 10.1002/bit.10162

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  10 in total

Review 1.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

2.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

Review 3.  Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies.

Authors:  Nathalie Clément; David R Knop; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

4.  Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury.

Authors:  Nobutaka Shimizu; Mark F Doyal; William F Goins; Katsumi Kadekawa; Naoki Wada; Anthony J Kanai; William C de Groat; Akihide Hirayama; Hirotsugu Uemura; Joseph C Glorioso; Naoki Yoshimura
Journal:  Neuroscience       Date:  2017-09-20       Impact factor: 3.590

5.  Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin.

Authors:  Hitoshi Yokoyama; Katsumi Sasaki; Michael E Franks; William F Goins; James R Goss; William C de Groat; Joseph C Glorioso; Michael B Chancellor; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

Review 6.  Gene therapy as future treatment of erectile dysfunction.

Authors:  Naoki Yoshimura; Ryuichi Kato; Michael B Chancellor; Joel B Nelson; Joseph C Glorioso
Journal:  Expert Opin Biol Ther       Date:  2010-09       Impact factor: 4.388

7.  Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectors.

Authors:  Seiji Kuroda; Yoshitaka Miyagawa; Makoto Sukegawa; Taro Tomono; Motoko Yamamoto; Kumi Adachi; Gianluca Verlengia; William F Goins; Justus B Cohen; Joseph C Glorioso; Takashi Okada
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-13       Impact factor: 5.849

8.  Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury.

Authors:  R Kato; D Wolfe; C H Coyle; J B Wechuck; P Tyagi; T Tsukamoto; J B Nelson; J C Glorioso; M B Chancellor; N Yoshimura
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

9.  Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification.

Authors:  Canping Jiang; James B Wechuck; William F Goins; David M Krisky; Darren Wolfe; Mohammad M Ataai; Joseph C Glorioso
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early Genes.

Authors:  Seiji Kuroda; Yoshitaka Miyagawa; Yuriko Sato; Motoko Yamamoto; Kumi Adachi; Hiromi Kinoh; William F Goins; Justus B Cohen; Joseph C Glorioso; Nobuhiko Taniai; Hiroshi Yoshida; Takashi Okada
Journal:  Mol Ther Methods Clin Dev       Date:  2020-03-17       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.